Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day

MENLO PARK, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that company management will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum | Oncology Day on Thursday, February 14, 2019 at 1:00 p.m. ET in New York.

A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at www.fortyseveninc.com. A replay of the webcast will be available on the Forty Seven website for 90 days following the event.

About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma and colorectal carcinoma.

For more information please visit www.fortyseveninc.com or contact [email protected].

For journalist enquiries please contact Sarah Plumridge at [email protected] or phone (312) 506-5218.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at [email protected] or phone (212) 362-1200.